SCLERO.ORG
Search
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Autoimmune
Media Stories
Scleroderma
ISN/Website
Scleroderma Archive
We maintain news archives for the most recent 3 years.
2020: Jan Feb Mar Apr May Jun Jul Aug Sep
2020 - 2019 - 2018 - 2017

September 2020 Scleroderma News

Subclinical atherosclerosis in systemic sclerosis (SSc) and rheumatoid arthritis (RA): a comparative matched-cohort study. The results of this comparative study show that subclinical atherosclerosis is comparable between SSc and RA, a systemic disease with well-defined high atherosclerotic burden. PubMed, Rheumatol Int, 08/08/2020. (Also see Cardiac (Heart) Involvement and Symptoms and Complications of Rheumatoid Arthritis)

Clinicopathological characteristics of lung cancer in patients with systemic sclerosis (SSc). A high proportion of patients had SSc-interstitial lung disease, including non specific interstitial pneumonia and usual interstitial pneumonia. PubMed, Clin Respir J, 08/08/2020. (Also see Lung Involvement and Cancer)

Low B cell counts as risk factor for infectious complications in systemic sclerosis after autologous hematopoietic stem cell transplantation (aHSCT). After aHSCT, monitoring for infectious complications, especially for cytomegalovirus reactivations, is crucial as the reconstitution of the immune system takes longer than 12 months. PubMed, Arthritis Res Ther, 2020 Aug 8;22(1):183. (Also see Stem Cell (Bone Marrow) Transplantation and B Cells and T Cells)

Scleroderma of the Hand: Evaluation and Treatment. The spectrum of hand manifestations seen in patients with scleroderma will be reviewed with the focus on evaluation and management. PubMed, J Am Acad Orthop Surg, 2020 Aug 15;28(16):e686-e695. (Also see Hand and Joint Involvement)

Case Report: Etiologic role of Borrelia burgdorferi in morphea. After diagnosis of morphea was established, and with systemic therapy (corticosteroids and methotrexate), the evolution was favorable. PubMed, Exp Ther Med. (Also see Causes of Morphea)

Rituximab (RTX) as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease (SSc-ILD) unresponsive to conventional immunosuppression. Based on our results, RTX's use as an add-on treatment to MMF appears to be effective as a rescue therapy in patients with a more aggressive SSc-ILD phenotype. Seminars in Arthritis and Rheumatism, 08/08/2020. (Also see Cellcept and Biologic Agents)

Association of functional (GA)n microsatellite polymorphism in the FLI1 gene with susceptibility to human systemic sclerosis (SSc). Extended repeat alleles of FLI1 (GA)n microsatellite may be associated with lower FLI1 mRNA levels and susceptibility to human SSc. PubMed, Rheumatology (Oxford), 2020 Jul 22;keaa306. (Also see Genetics)

Targeting the α7 nicotinic acetylcholine receptor - a novel road towards the future treatment of skin diseases. Emphasis on translational research targeting the α7nAChR in skin may lead to the development of new treatment and prevention modalities against fibrosclerotic skin diseases. PubMed, Exp Dermatol, 08/11/2020. (Also see Skin Fibrosis)

CD47 prevents the elimination of diseased fibroblasts in scleroderma. Our study demonstrates the efficiency of combining different immunotherapies in treating scleroderma and provides a rationale for combining CD47 and IL-6 inhibition in clinical trials. PubMed, JCI Insight, 2020 Aug 20;5(16):140458. (Also see Fibroblasts)

Biomarker profiles of endothelial activation and dysfunction in rare systemic autoimmune diseases: implications for cardiovascular risk. Chronic inflammatory connective tissue diseases -specific biomarker profiles revealed an anti-angiogenic, interferon-driven environment during active disease. PubMed, Rheumatology (Oxford), 2020 Aug 18;keaa270. (Also see Vascular Involvement)

Go to Scleroderma Medical News: August 2020
 

We have the world's best supporters! See ISN News.

 

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected]. Disclaimer. Privacy Policy.
 

The most important thing in the world to know about scleroderma is sclero.org!